Clinical utility of circulating tumor cell measurement in the diagnosis of indeterminate lesions of the pancreas.
The quantification of circulating tumor cells has been historically problematic due to the different methods applied to their measurement. Following the development of standardized technology, they are now becoming well-established prognostic and predictive markers in patients with breast, colon and prostate cancer. While they represent a real-time noninvasive test, their use in diagnostics has seldom been reported. We report their use to help diagnose an indeterminate pancreatic mass. The use of an automated circulating tumor cell platform as described is likely to have utility as an aid to differential diagnosis, although larger studies will be required to ascertain its positive or negative predictive value.
Mudan
Satvinder
S
Department of Surgery, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK. satvinder.mudan@rmh.nhs.uk
Giakoustidis
Alexandros
A
Thillainayagam
Andrew V
AV
Jacob
Jimmy
J
Stebbing
Justin
J
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D006403:Hematologic Tests / Q000379:methods*; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D014057:Tomography, X-Ray Computed
D014408:Biomarkers, Tumor